Novartis Sandoz Unit Gets FDA Approval for Multiple Sclerosis Biosimilar

Novartis is a Fair360 Top 50 Hall of Fame company.


Sandoz, Novartis’ generic-drugs division, received approval from the U.S. Food and Drug Administration (FDA) for a biosimilar medicine to treat relapsing forms of multiple sclerosis.

Tyruko is the first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis.

“Of the nearly one million people in the US living with multiple sclerosis, hundreds of thousands experience disease relapse. Tyruko has the potential to extend the reach of natalizumab treatment for these patients, increase healthcare savings and fuel innovation through competition in the market,” said Keren Haruvi, President of North America, Sandoz Inc.

Click here to read more.